Briacell Therapeutics Corp (BCTX)

$3.55 -0.01 (-0.28%)
Market Cap 31.58M
Revenue (ttm) 0.00
Net Income (ttm) -26.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 56,045
Avg Vol 327,120
Day's Range N/A - N/A
Shares Out 8.70M
Stochastic %K 40%
Beta 1.10
Analysts Strong Buy
Price Target $40.00

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 921 1810
Fax: 604 921 1898
Address:
Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada
georgeyann
georgeyann Sep. 15 at 2:29 PM
$BCTX bot 500 shares!
0 · Reply
BCTX20bMC
BCTX20bMC Sep. 14 at 11:00 PM
$BCTX moved 5%+ AH from 10 shares….when she rockets …it will be mind blowing. 🌋🌋🌋
1 · Reply
Firstvik
Firstvik Sep. 14 at 10:25 PM
$BCTX And the market goes mild! Dilution next up lol
2 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 7:33 PM
Innovation in cancer research continues. 🧬 $BCTX BriaCell Therapeutics Corp. announced a seventh consecutive positive DSMB recommendation for its pivotal Phase 3 Bria-ABC study of Bria-IMT™ plus an immune checkpoint inhibitor. The company continues advancing its immunotherapy program for metastatic breast cancer. NEWS: https://bit.ly/46Ho2b3 #BCTX #CancerResearch #Immunotherapy
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 6:55 PM
Innovation in cancer research continues. 🧬 $BCTX BriaCell Therapeutics Corp. announced a seventh consecutive positive DSMB recommendation for its pivotal Phase 3 Bria-ABC study of Bria-IMT™ plus an immune checkpoint inhibitor. The company continues advancing its immunotherapy program for metastatic breast cancer. #BCTX #CancerResearch #Immunotherapy
0 · Reply
AliceFireSteam
AliceFireSteam Sep. 14 at 6:55 PM
$BCTX Just to remind everyone that after tomorrow they are allowed to dilute again, so don't be surprised if it happens.
1 · Reply
Merlintrader
Merlintrader Sep. 14 at 4:57 PM
BriaCell ($BCTX) Stock Hub: Seventh DSMB Recommendation to Continue Phase 3 https://www.merlintrader.com/briacell-therapeutics-stock-hub/
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 3:54 PM
BriaCell Therapeutics Corp. $BCTX is developing novel immunotherapies for patients with metastatic breast cancer. Its pivotal Phase 3 Bria-ABC study is evaluating Bria-IMT™ plus an immune checkpoint inhibitor. The seventh consecutive positive DSMB recommendation marks another milestone in the program. NEWS: https://bit.ly/46Ho2b3 #BCTX #Immunotherapy #BiotechStocks
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 3:47 PM
BB's Stock Haven : Another key milestone for $BCTX: the ind... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177954881 via @Investors_Hub
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 3:44 PM
$BCTX BriaCell Therapeutics Corp. continues its Phase 3 Bria-ABC study under FDA Fast Track designation. The latest independent DSMB review recommends continuing the study without modifications. Clinical-stage biotech remains an area to watch. 🔬 NEWS: https://bit.ly/46Ho2b3 #BCTX #Biotech #FDA #Stocks
0 · Reply
Latest News on BCTX
BriaCell (BCTX) Phase 3 Trial Safety Endorsement Highlights Market's Cautious Outlook

2026-09-14T12:52:23.000Z - 1 day ago

BriaCell (BCTX) Phase 3 Trial Safety Endorsement Highlights Market's Cautious Outlook

BriaCell announces DSMB recommendation to continue Bria-ABC study

2026-09-14T11:35:52.000Z - 1 day ago

BriaCell announces DSMB recommendation to continue Bria-ABC study

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

Mon, 14 Sep 2026 07:30:00 -0400 - 1 day ago

Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study

BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

Tue, 08 Sep 2026 07:30:00 -0400 - 7 days ago

BriaCell's Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center

BriaCell (BCTX) Advances Melanoma Vaccine Development Amid Challenging Valuation Metrics

2026-08-24T12:57:02.000Z - 22 days ago

BriaCell (BCTX) Advances Melanoma Vaccine Development Amid Challenging Valuation Metrics

BriaCell advances melanoma immunotherapy vaccine candidate Bria-MEL+

2026-08-24T11:35:06.000Z - 22 days ago

BriaCell advances melanoma immunotherapy vaccine candidate Bria-MEL+

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™

Mon, 24 Aug 2026 07:30:00 -0400 - 22 days ago

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™

BriaCell gets FDA clearance for Bria-PROS+ study in prostate cancer

2026-08-05T13:46:04.000Z - 5 weeks ago

BriaCell gets FDA clearance for Bria-PROS+ study in prostate cancer

BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer

Wed, 05 Aug 2026 07:30:00 -0400 - 5 weeks ago

BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer

BriaCell (BCTX) Expands Phase 3 Study with New Clinical Site

2026-07-16T13:27:49.000Z - 2 months ago

BriaCell (BCTX) Expands Phase 3 Study with New Clinical Site

BriaCell announces Odette Cancer Centre joins Bria-IMT trial

2026-07-16T11:40:48.000Z - 2 months ago

BriaCell announces Odette Cancer Centre joins Bria-IMT trial

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

Thu, 16 Jul 2026 07:30:00 -0400 - 2 months ago

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

BriaCell (BCTX) Partners with Fujifilm for Cell Therapy Manufacturing

2026-07-15T13:32:56.000Z - 2 months ago

BriaCell (BCTX) Partners with Fujifilm for Cell Therapy Manufacturing

BriaCell arranges scalable manufacturing with Fujifilm Biotechnologies

2026-07-15T12:10:22.000Z - 2 months ago

BriaCell arranges scalable manufacturing with Fujifilm Biotechnologies

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™

Wed, 15 Jul 2026 07:30:00 -0400 - 2 months ago

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

Tue, 07 Jul 2026 07:30:00 -0400 - 2 months ago

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

BriaCell Partners With Uneedle To Support Scalable Microneedle Delivery Of Bria-IMT

2026-06-26T10:06:07.000Z - 2 months ago

BriaCell Partners With Uneedle To Support Scalable Microneedle Delivery Of Bria-IMT

BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development

2026-06-25T13:25:58.000Z - 2 months ago

BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development

BriaCell enters MoU with Uneedle for microneedle technology

2026-06-25T11:45:30.000Z - 2 months ago

BriaCell enters MoU with Uneedle for microneedle technology

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

Thu, 25 Jun 2026 07:30:00 -0400 - 2 months ago

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

BriaCell Therapeutics Announces Closing of Offering

Tue, 02 Jun 2026 16:05:00 -0400 - 3 months ago

BriaCell Therapeutics Announces Closing of Offering

BriaCell Presents Positive Clinical Data at ASCO 2026

Mon, 01 Jun 2026 07:30:00 -0400 - 3 months ago

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics Announces Pricing of Offering

Sun, 31 May 2026 19:59:00 -0400 - 3 months ago

BriaCell Therapeutics Announces Pricing of Offering

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

2026-05-26T14:43:01.000Z - 3 months ago

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

2026-05-26T13:05:39.000Z - 3 months ago

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

Tue, 26 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

2026-05-22T13:27:19.000Z - 3 months ago

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

BriaCell announces data from Bria-IMT at ASCO 2026

2026-05-22T11:49:02.000Z - 3 months ago

BriaCell announces data from Bria-IMT at ASCO 2026

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Fri, 22 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

Fri, 15 May 2026 07:30:00 -0400 - 4 months ago

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

2026-05-14T15:31:53.000Z - 4 months ago

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

Thu, 14 May 2026 07:30:00 -0400 - 4 months ago

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

2026-05-13T16:39:28.000Z - 4 months ago

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

2026-05-13T14:41:55.000Z - 4 months ago

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Wed, 13 May 2026 07:30:00 -0400 - 4 months ago

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Tue, 12 May 2026 07:30:00 -0400 - 4 months ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Thu, 07 May 2026 07:30:00 -0400 - 4 months ago

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

2026-05-07T04:03:56.000Z - 4 months ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

Wed, 06 May 2026 07:30:00 -0400 - 4 months ago

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

Mon, 27 Apr 2026 07:30:00 -0400 - 4 months ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

2026-04-21T13:28:43.000Z - 4 months ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

BriaCell presents anti-cancer activity of Bria-OTS

2026-04-21T11:54:23.000Z - 4 months ago

BriaCell presents anti-cancer activity of Bria-OTS

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

Tue, 21 Apr 2026 07:30:00 -0400 - 4 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

2026-04-20T13:32:04.000Z - 4 months ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

2026-04-20T11:41:56.000Z - 4 months ago

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Mon, 20 Apr 2026 07:30:00 -0400 - 4 months ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

Tue, 31 Mar 2026 16:05:00 -0400 - 5 months ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

2026-03-18T13:30:56.000Z - 6 months ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

BriaCell to present four posters at the 2026 AACR

2026-03-18T11:42:55.000Z - 6 months ago

BriaCell to present four posters at the 2026 AACR

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Wed, 18 Mar 2026 07:30:00 -0400 - 6 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Mar 10, 2026, 7:30 AM EDT - 6 months ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

Mar 5, 2026, 4:04 PM EST - 6 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

2026-02-18T22:35:25.000Z - 6 months ago

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

Feb 18, 2026, 5:30 PM EST - 6 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

2026-02-17T12:40:59.000Z - 7 months ago

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

BriaCell says patient images show regression, resolution of metastsized tumors

2026-01-28T12:40:40.000Z - 7 months ago

BriaCell says patient images show regression, resolution of metastsized tumors

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

Jan 28, 2026, 7:30 AM EST - 7 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

2026-01-27T12:41:04.000Z - 7 months ago

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

Jan 27, 2026, 7:30 AM EST - 7 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

Jan 15, 2026, 4:05 PM EST - 8 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

Jan 13, 2026, 9:00 PM EST - 8 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

BriaCell Therapeutics trading resumes

2026-01-13T14:41:11.000Z - 8 months ago

BriaCell Therapeutics trading resumes

BriaCell Therapeutics trading halted, volatility trading pause

2026-01-13T14:35:29.000Z - 8 months ago

BriaCell Therapeutics trading halted, volatility trading pause

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Jan 13, 2026, 7:30 AM EST - 8 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

Dec 18, 2025, 7:30 AM EST - 9 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

Dec 10, 2025, 7:30 AM EST - 9 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Dec 9, 2025, 7:30 AM EST - 9 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Dec 2, 2025, 7:30 AM EST - 9 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 9 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 20, 2025, 7:30 AM EST - 9 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 18, 2025, 7:30 AM EST - 10 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 7, 2025, 7:30 AM EST - 10 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Nov 4, 2025, 7:30 AM EST - 10 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:50 AM EDT - 10 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 21, 2025, 7:30 AM EDT - 10 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 20, 2025, 7:30 AM EDT - 11 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 11 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Oct 3, 2025, 7:30 AM EDT - 11 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 26, 2025, 7:30 AM EDT - 1 year ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 25, 2025, 7:30 AM EDT - 1 year ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 21, 2025, 12:00 PM EDT - 1 year ago

BriaCell Announces Proposed Effective Date of Share Consolidation

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Aug 13, 2025, 7:30 AM EDT - 1 year ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

georgeyann
georgeyann Sep. 15 at 2:29 PM
$BCTX bot 500 shares!
0 · Reply
BCTX20bMC
BCTX20bMC Sep. 14 at 11:00 PM
$BCTX moved 5%+ AH from 10 shares….when she rockets …it will be mind blowing. 🌋🌋🌋
1 · Reply
Firstvik
Firstvik Sep. 14 at 10:25 PM
$BCTX And the market goes mild! Dilution next up lol
2 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 7:33 PM
Innovation in cancer research continues. 🧬 $BCTX BriaCell Therapeutics Corp. announced a seventh consecutive positive DSMB recommendation for its pivotal Phase 3 Bria-ABC study of Bria-IMT™ plus an immune checkpoint inhibitor. The company continues advancing its immunotherapy program for metastatic breast cancer. NEWS: https://bit.ly/46Ho2b3 #BCTX #CancerResearch #Immunotherapy
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 6:55 PM
Innovation in cancer research continues. 🧬 $BCTX BriaCell Therapeutics Corp. announced a seventh consecutive positive DSMB recommendation for its pivotal Phase 3 Bria-ABC study of Bria-IMT™ plus an immune checkpoint inhibitor. The company continues advancing its immunotherapy program for metastatic breast cancer. #BCTX #CancerResearch #Immunotherapy
0 · Reply
AliceFireSteam
AliceFireSteam Sep. 14 at 6:55 PM
$BCTX Just to remind everyone that after tomorrow they are allowed to dilute again, so don't be surprised if it happens.
1 · Reply
Merlintrader
Merlintrader Sep. 14 at 4:57 PM
BriaCell ($BCTX) Stock Hub: Seventh DSMB Recommendation to Continue Phase 3 https://www.merlintrader.com/briacell-therapeutics-stock-hub/
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 3:54 PM
BriaCell Therapeutics Corp. $BCTX is developing novel immunotherapies for patients with metastatic breast cancer. Its pivotal Phase 3 Bria-ABC study is evaluating Bria-IMT™ plus an immune checkpoint inhibitor. The seventh consecutive positive DSMB recommendation marks another milestone in the program. NEWS: https://bit.ly/46Ho2b3 #BCTX #Immunotherapy #BiotechStocks
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 3:47 PM
BB's Stock Haven : Another key milestone for $BCTX: the ind... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177954881 via @Investors_Hub
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 3:44 PM
$BCTX BriaCell Therapeutics Corp. continues its Phase 3 Bria-ABC study under FDA Fast Track designation. The latest independent DSMB review recommends continuing the study without modifications. Clinical-stage biotech remains an area to watch. 🔬 NEWS: https://bit.ly/46Ho2b3 #BCTX #Biotech #FDA #Stocks
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 3:41 PM
$BCTX: 7th consecutive positive - WINNERS CIRCLE https://investorshangout.com/post/view?id=6844429
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 3:25 PM
BB's Stock Haven : Another key milestone for $BCTX : the ind... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177955240 via @Investors_Hub
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 2:58 PM
Positive safety update for $BCTX! BriaCell’s independent Data Safety Monitoring Board has issued its seventh consecutive recommendation to continue the pivotal Phase 3 study. No safety or other clinical concerns were raised in the latest review. NEWS: https://bit.ly/46Ho2b3 #BCTX #CancerResearch #HealthcareStocks
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 2:38 PM
🚨 $BCTX NEWS ALERT 🚨 BriaCell Therapeutics Corp. announces its seventh consecutive positive DSMB recommendation for the pivotal Phase 3 Bria-ABC study in metastatic breast cancer. The independent board found no safety or other clinical concerns and recommended continuing without modifications. NEWS: https://bit.ly/46Ho2b3 #BCTX #Biotech #CancerResearch #Stocks
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 2:24 PM
Whale Team : Independent DSMB recommends continuing $BCTX's pivotal Phase 3... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177954938 via @Investors_Hub
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 2:16 PM
Another key milestone for $BCTX: the independent DSMB has again recommended continuing BriaCell's Phase 3 Bria-ABC study with no safety concerns identified. This marks the 7th consecutive positive DSMB review. #CancerResearch #Biotech NEWS: https://bit.ly/46Ho2b3 #BCTX
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 2:02 PM
BriaCell Therapeutics Corp ( $BCTX ): $BCTX: 7th consecutive positive DSMB rec... https://investorshub.advfn.com/boards/read_msg.aspx?message_id=177954763 via @Investors_Hub
0 · Reply
SmallCapGrowth
SmallCapGrowth Sep. 14 at 1:49 PM
$BCTX: 7th consecutive positive DSMB recommendation for the Phase 3 Bria-ABC study in metastatic breast cancer. The independent board reported no safety concerns and recommended the trial continue without modifications. #Biotech #BreastCancer NEWS: https://bit.ly/46Ho2b3
0 · Reply
AliceFireSteam
AliceFireSteam Sep. 14 at 11:40 AM
$BCTX 7th continue as usual, let's go
0 · Reply
BABYLENNY
BABYLENNY Sep. 14 at 11:37 AM
$BCTX Here we go..its coming.
0 · Reply
JediGreen
JediGreen Sep. 14 at 11:37 AM
$BCTX
0 · Reply
JediGreen
JediGreen Sep. 14 at 11:36 AM
$BCTX Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell's Phase 3 Metastatic Breast Cancer Study https://feeds.issuerdirect.com/news-release.html?newsid=5576870725019346&symbol=BCTX
0 · Reply